




Searching News Database: KEYTRUDA
HSMN NewsFeed - 3 Apr 2024
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
HSMN NewsFeed - 28 Oct 2021
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
HSMN NewsFeed - 2 Aug 2021
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
HSMN NewsFeed - 17 May 2021
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors
HSMN NewsFeed - 11 Mar 2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
HSMN NewsFeed - 4 Sep 2020
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
HSMN NewsFeed - 7 Jul 2020
HiberCell Announces Acquisition of Biothera Pharmaceuticals' Imprime PGG Program
HiberCell Announces Acquisition of Biothera Pharmaceuticals' Imprime PGG Program
HSMN NewsFeed - 29 Oct 2018
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
HSMN NewsFeed - 15 Oct 2018
Medivir to Focus on its Clinical Development and Appoints Uli Hacksell as Acting CEO
Medivir to Focus on its Clinical Development and Appoints Uli Hacksell as Acting CEO
HSMN NewsFeed - 4 Apr 2016
BioLineRx's Novel Treatment for Non-Surgical Removal of Skin Lesions Receives CE Mark Approval
BioLineRx's Novel Treatment for Non-Surgical Removal of Skin Lesions Receives CE Mark Approval
HSMN NewsFeed - 6 Jan 2016
NextCure, Inc., New Immuno-Oncology Firm, Announces $67 Million Series A Financing
NextCure, Inc., New Immuno-Oncology Firm, Announces $67 Million Series A Financing
HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
HSMN NewsFeed - 1 Oct 2015
Synthetic Biologics Appoints Raymond Stapleton, PhD, as Senior Vice President, Manufacturing
Synthetic Biologics Appoints Raymond Stapleton, PhD, as Senior Vice President, Manufacturing